All In Biotech

Drug Trial Radar · NCT01631266

Comparison of Diagnostic Performance of C-Tb to QuantiFERON®-TB, in Combination With a Safety Assessment of C-Tb vs Tuberculin PPD RT23 SSI

A Phase III Contact Tracing Trial Comparing the Diagnostic Performance of C-Tb to QuantiFERON®-TB Gold In-Tube, in Combination With a Double Blind Randomized Split Body Safety Assessment of C-Tb Versus 2 T.U. Tuberculin PPD RT23 SSI

Last checked: Nov 19, 2026Latest source record: Apr 17, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 979 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

979

Actual

Start

Jul 2012

Primary completion

Oct 2014

Study completion Oct 2014

Sponsor

Lead sponsor
Statens Serum InstitutAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 29, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Diagnostic
Who can join
All sexes, from 6 weeks, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Tuberculosis (TB) continues to be the most important bacterial infection worldwide and therefore new improved diagnostic tests are needed to help doctors in diagnosing TB. We are investigating a new skin test named C-Tb. Like the current tuberculin skin test (PPD), the C-Tb test is injected just under the skin and will, when positive, show redness and/or swelling at the injection site while a negative test will leave no reactions. The aim of this trial is to test the C-Tb skin test in volunteers. The volunteers are divided into four groups: * Negative control group: Must have no history of exposure to a person with tuberculosis disease. * Occasional contact: Must be in contact with a person with tuberculosis disease between 6 hours/week and 6 hours/day * Close contact: Must be in close contact with a person with tuberculosis disease for more than 6 hours/day for at least five days * Positive control group: Must have a confirmed tuberculosis disease within the last 3 years. The goals of this clinical trial are: * To compare the C-Tb test to a blood test, the QuantiFERON test. * To compare the C-Tb test to the PPD test that is currently being used. * To assess the safety of the C-Tb test.

Conditions

  • Tuberculosis

Interventions

  • C-TbBiological

    The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme

  • 2 T.U. Tuberculin PPD RT 23 SSIBiological

    The 2 T.U. Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To demonstrate an increasing trend in C-Tb test positivity across the four study groups, with 'positivity' defined as an induration ≥ 5 mmTime frame: Onset between the injections and 28 days after the injections

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital Universitario de Cruces

    Barakaldo, Basque Country, Spain

  • CAP Drassanes, Unitat de Prevenció i Control de Tuberculosi

    Barcelona, Catalonia, Spain

  • Hospital del Mar

    Barcelona, Catalonia, Spain

  • Public Health Agency of Barcelona

    Barcelona, Catalonia, Spain

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Catalonia, Spain

  • Hospital Vall d'Hebron

    Barcelona, Catalonia, Spain

  • Hospital Clínic i Provincial de Barcelona

    Barcelona, Catalonia, Spain

  • Hospital Mutua de Terrassa

    Barcelona, Catalonia, Spain

  • Hospital San Joan De Deu

    Barcelona, Catalonia, Spain

  • Hospital Universitario Lucus Augusti

    Lugo, Galicia, Spain

  • Complexo Hospitalario de Pontevedra

    Pontevedra, Galicia, Spain

  • Complejo Hospitalario Universitario de Santiago

    Santiago de Compostela, Galicia, Spain

  • Complexo Hospitalario Universitario de Vigo

    Vigo, Galicia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.